Innovative approaches, such as the development of allosteric inhibitors or dual inhibitors targeting multiple pathways (e.g., JAK2 and FLT3), may offer more effective treatments for leukemia subtypes that are refractory to current therapies. The gene discussed is FLT3; the disease is leukemia.